Drug research

Temozolomide

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as TMZ; Temodar

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant GliomaNCT00589875	CADL	Phase 2	Completed	2015-12Actual
ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma MultiformeNCT04587830	Polaris Group	Phase 2	Active not recruiting	2027-02-28Estimated
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)NCT06346067	ERAS	Phase 3	Active not recruiting	2028-04Estimated
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed GlioblastomaNCT06556563	NovoCure GmbH	Phase 3	Recruiting	2029-04Estimated

CADLCompletedPrimary completion: 2015-12 · Actual

Trial details

Polaris GroupActive not recruitingPrimary completion: 2027-02-28 · Estimated

Trial details

ERASActive not recruitingPrimary completion: 2028-04 · Estimated

Trial details

NovoCure GmbHRecruitingPrimary completion: 2029-04 · Estimated

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.